The industry continues to adopt more single-use, and limited multi-use, components and systems for process development and production operations. In addition, biotech firms are building and retrofitting their facilities so they will provide more flexibility when product priorities change and multiple products must be produced at the same time. In addition, these facilities must support products at various phases of clinical evaluation, plus when they are approved for licensed production…
JUST PUBLISHED: "Standardized and GMP-Ready, Closed-System Processing of Expanded Adipose-Derived Stem Cells Using the Gibco CTS
Rotea System Across 2D and 3D Bioreactor Expansions." Click on the OPEN ACCESS ARTICLES tab below.
